Molecular assays in breast cancerpathology

Pathology

Volumn 43, Issue 2, 2011, Pages 116-127

  O'toole, Sandra A ^a,b,c,d   Selinger, Christina I ^a   Millar, Ewan K A ^b,e,f,g   Lum, Trina ^a   Beith, Jane M ^a,b,c,f  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ST VINCENT'S CLINIC   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f ST GEORGE HOSPITAL   (Australia)

^g UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Breast cancer; Chromosome 17; HER2; In situ hybridisation; MammaPrint; Molecular assays; Oncotype DX; Prognostic biomarkers; TOP2A

Indexed keywords

DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN;

BREAST TUMOR; CHROMOSOME 17; CHROMOSOME ABERRATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METHODOLOGY; MOLECULAR DIAGNOSIS; NUCLEIC ACID AMPLIFICATION; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROTO ONCOGENE; REVIEW;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MOLECULAR DIAGNOSTIC TECHNIQUES; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PROGNOSIS;

EID: 79955973200     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e3283430926     Document Type: Review

References (103)

1. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000; 355: 1822. (Pubitemid 30265099)
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
3. Jensen E, DeSombre E, Jungblutp. Estrogen receptors in hormone responsive tissues and tumours. Chicago: University of Chicagopress; 1969.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82. (Pubitemid 17231334)
5. Slamon DJ.proto-oncogenes and human cancers. N Engl J Med 1987; 317: 955-7. (Pubitemid 17147940)
6. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecularportraits of human breast tumours. Nature 2000; 406: 747-52.
7. Barros FF,powe DG, Ellis IO, Green AR. Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology 2010; 56: 560-72.
8. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neuproto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12. (Pubitemid 19147683)
9. Bartlett JM, Ellis IO, Dowsett M, et al. Human epidermal growth factor receptor 2 status correlates with lymph node involvement inpatients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol 2007; 25: 4423-30. (Pubitemid 350013848)
10. Farshid G, Armes JE, Bell R, et al. Establishment of the Australian in situ hybridizationprogram for the assessment of HER2 amplification in breast cancer: A model for the introduction of new biomarkers into clinicalpractice. Diagn Molpathol 2010; 19: 187-93.
11. Hudis CA. Trastuzumab-mechanism of action and use in clinicalpractice. N Engl J Med 2007; 357: 39-51.
12. Romond EH,perez EA, Bryant J, et al. Trastuzumabplus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84. (Pubitemid 41464706)
13. Piccart-Gebhart MJ,Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72. (Pubitemid 41464705)
14. Joensuu H, Kellokumpu-LehtinenpL, Bonop, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-20. (Pubitemid 43290919)
15. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a metaanalysis ofpublished randomized trials. BMC Cancer 2007; 7: 153.
16. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH.prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010; 28: 92-8.
17. Geyer CE, Forster J, Lindquist D, et al. Lapatinibplus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43. (Pubitemid 46021510)
18. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that hasprogressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48. (Pubitemid 29415219)
19. Mass RD,press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005; 6: 240-6. (Pubitemid 47050800)
20. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26. (Pubitemid 34111379)
21. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of Americanpathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-45. (Pubitemid 350003059)
22. Penault-Llorca F, Bilous M, Dowsett M, et al. Emerging technologies for assessing HER2 amplification. Am J Clinpathol 2009; 132: 539-48.
23. van de Vijver M, Bilous M, Hanna W, et al. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res 2007; 9: R68.
24. Bilous M, Morey A, Armes J, Cummings M, Francis G. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancerproduces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.pathology 2006; 38: 120-4.
25. Papouchado BG, Myles J, Lloyd RV, et al. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am J Surgpathol 2010; 34: 767-76.
26. Sauter G, Lee J, Bartlett JM, Slamon DJ,press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009; 27: 1323-33.
27. Dowsett M, Hanna WM, Kockx M, et al. Standardization of HER2 testing: results of an internationalproficiency-testing ring study. Mod pathol 2007; 20: 584-91. (Pubitemid 46632000)
28. Marchio C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy numberpredictpolysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009; 219: 16-24.
29. Troxell ML, Bangs CD, Lawce HJ, et al. Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus. Am J Clinpathol 2006; 126: 709-16. (Pubitemid 44707621)
30. Viale G. Beprecise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer. J Pathol 2009; 219: 1-2.
31. Bartlett JM, Campbell FM, Mallon EA. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined? Am J Clinpathol 2008; 130: 920-6.
32. Watters AD, Going JJ, Cooke TG, Bartlett JM. Chromosome 17 aneusomy is associated withpoorprognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 2003; 77: 109-14. (Pubitemid 36197611)
33. Bartlett JM, Campbell FM, Ibrahim M, et al. A UK NEQAS ICC and ISH multicentre study using the Kreatechposeidon HER2 FISHprobe: intersite variation can be rigorously controlled using FISH. Histopathology 2010; 56: 297-304.
34. Pathologists CMaCCCoA. Clinical laboratory assays for HER-2/neu amplification and overexpression: Quality assurance, standardisation, andproficiency testing. Archpathol Lab Med 2002; 126: 803-8.
35. Morey AL, Buckland M, O'Toole S, et al. Clonal heterogeneity of HER amplification: Nodal metastasis from a minority clone. RCPA Updates Sydney, 2009.
36. Hurtado A, Holmes KA, Geistlinger TR, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008; 456: 663-6.
37. Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB, Rose C. Value of epidermal growth factor receptor, HER2,p53, and steroid receptors inpredicting the efficacy of tamoxifen in high-riskpostmenopausal breast cancerpatients. J Clin Oncol 2001; 19: 3376-84. (Pubitemid 32642190)
38. Dowsett M, Houghton J, Iden C, et al. Benefit from adjuvant tamoxifen therapy inprimary breast cancerpatients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006; 17: 818-26.
39. Ryden L, Jirstrom K, BendahlpO, et al. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen inpremenopausal breast cancer. J Clin Oncol 2005; 23: 4695-704. (Pubitemid 46224072)
40. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy- Thind B. HER-2 and topoisomerase II aspredictors of response to chemotherapy. J Clin Oncol 2008; 26: 736-44. (Pubitemid 351264386)
41. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354: 2103-11. (Pubitemid 43736610)
42. Paik S, Bryant J,park C, et al. erbB-2 and response to doxorubicin inpatients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: 1361-70. (Pubitemid 28439960)
43. Dhesy-Thind B,pritchard KI, Messersmith H, O'Malley F, Elavathil L, Trudeau M. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat 2008; 109: 209-29. (Pubitemid 351644854)
44. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances andpharmacologic developments in antitumor activity and cardiotoxicity.pharmacol Rev 2004; 56: 185-229. (Pubitemid 38720829)
45. Levine MN,pritchard KI, Bramwell VH, Shepherd LE, Tu D,paul N. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil inpremenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005; 23: 5166-70. (Pubitemid 46224025)
46. Poole CJ, Earl HM, Hiller L, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 2006; 355: 1851-62. (Pubitemid 44664643)
47. Munro AF, Cameron DA, Bartlett JM. Targeting anthracyclines in early breast cancer: new candidatepredictive biomarkers emerge. Oncogene 2010; 29: 5231-40.
48. Pegram MD, Finn RS, Arzoo K, Beryt M,pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997; 15: 537-47. (Pubitemid 27384731)
49. Nielsen KV, Ejlertsen B, Moller S, et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol 2008; 47: 725-34. (Pubitemid 351878451)
50. Konecny GE,pauletti G, Untch M, et al. Association between HER2, TOP2A, and response to anthracycline-basedpreoperative chemotherapy in high-riskprimary breast cancer. Breast Cancer Res Treat 2010; 120: 481-9.
51. Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M. Triple negative breast cancer-current status andprospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomedpap Med Fac Univpalacky Olomouc Czech Repub 2009; 153: 13-7.
52. Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A. The role of topoisomerase IIalpha and HER-2 inpredicting sensitivity to anthracyclines in breast cancerpatients. Cancer Treat Rev 2009; 35: 662-7.
53. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999; 26: 142-50. (Pubitemid 29416439)
54. Glynn RW, Miller N, Whelan MC, Kerin MJ. Topoisomerase 2 alpha and the case for individualized breast cancer therapy. Ann Surg Oncol 2010; 17: 1392-7.
55. Tubbs R, Barlow WE, Budd GT, et al. Outcome ofpatients with earlystage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 2009; 27: 3881-6.
56. Tanner M, Isola J, Wiklund T, et al. Topoisomerase IIalpha gene amplificationpredicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neuamplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24: 2428-36. (Pubitemid 46630618)
57. Arriola E, Rodriguez-Pinilla SM, Lambros MB, et al. Topoisomerase II alpha amplification maypredict benefit from adjuvant anthracyclines in HER2positive early breast cancer. Breast Cancer Res Treat 2007; 106: 181-9. (Pubitemid 350045015)
58. Villman K, Sjostrom J, Heikkila R, et al. TOP2A and HER2 gene amplification aspredictors of response to anthracycline treatment in breast cancer. Acta Oncol 2006; 45: 590-6. (Pubitemid 44167211)
59. Bartlett JM, Munro AF, Dunn JA, et al.predictive markers of anthracycline benefit: aprospectivelyplanned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 2010; 11: 266-74.
60. Schindlbeck C, Mayr D, Olivier C, et al. Topoisomerase IIalpha expression rather than gene amplificationpredicts responsiveness of adjuvant anthracycline-based chemotherapy in women withprimary breast cancer. J Cancer Res Clin Oncol 2010; 136: 1029-37.
61. O'Malley FP, Chia S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009; 101: 644-50.
62. Kawachi K, Sasaki T, Murakami A, et al. The topoisomerase II alpha gene status inprimary breast cancer is apredictive marker of the response to anthracycline-based neoadjuvant chemotherapy.pathol Respract 2010; 206: 156-62.
63. Harris LN, Broadwater G, Abu-Khalaf M, et al. Topoisomerase II{alpha} amplification does notpredict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol 2009; 27: 3430-6.
64. Hagen AI, Bofin AM, Ytterhus B, et al. Amplification of TOP2A and HER-2 genes in breast cancers occurring inpatients harbouring BRCA1 germline mutations. Acta Oncol 2007; 46: 199-203.
65. Knoop AS, Knudsen H, Balslev E, et al. retrospective analysis of topoisomerase IIa amplifications and deletions aspredictive markers inprimary breast cancerpatients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23: 7483-90. (Pubitemid 46291811)
66. Slamon D, Eiermann W, Robert N, et al.Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2positive early breast cancerpatients: second interim efficacy analysis. San Antonio Breast Cancer Symposium, Dec 14-17, 2006, Abstract 52.
67. Mueller RE,parkes RK, Andrulis I, O'Malley FP. Amplification of the TOP2A gene does notpredict high levels of topoisomerase II alphaprotein in human breast tumor samples. Genes Chromosomes Cancer 2004; 39: 288-97. (Pubitemid 38326310)
68. Usha L, Tabesh B, Morrison LE, Rao RD, Jacobson K, Zhu A, et al. Topoisomerase II alpha gene copy loss has adverseprognostic significance in ERBB2-amplified breast cancer: a retrospective study ofparaffinembedded tumor specimens and medical charts. J Hematol Oncol 2008; 1: 12.
69. Pritchard KI. Are HER2 and TOP2A useful asprognostic orpredictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer? J Clin Oncol 2009; 27: 3875-6.
70. Reinholz MM, Jenkins RB, Hillman D, et al. The clinical significance ofpolysomy 17 in the HER2+ N9831 intergroup adjuvant trastuzumab trial. San Antonio Breast Cancer Symposium, Dec 13-16, 2007, Abstract 36.
71. Martin M, Mackey J, Vogel C. Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. Breast 2007; 16 (Suppl 2): S127-31.
72. Carlson RW, Brown E, Burstein HJ, et al. NCCN Task Force Report: Adjuvant therapy for breast cancer. J Natl Compr Canc Netw 2006; 4 (Suppl 1): S1-26.
73. Yu K, Lee CH, TanpH, Tanp. Conservation of breast cancer molecular subtypes and transcriptionalpatterns of tumorprogression across distinct ethnicpopulations. Clin Cancer Res 2004; 10: 5508-17. (Pubitemid 39100489)
74. Sorlie T,perou CM, Tibshirani R, et al. Gene expressionpatterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci USA 2001; 98: 10869-74. (Pubitemid 32878711)
75. Sorlie T, Tibshirani R,parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets.Proc Natl Acad Sci USA 2003; 100: 8418-23. (Pubitemid 36842560)
76. Weigelt B, Hu Z, He X, et al. Molecularportraits and 70-geneprognosis signature arepreserved throughout the metastaticProcess of breast cancer. Cancer Res 2005; 65: 9155-8. (Pubitemid 41507977)
77. Carey LA,perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-502. (Pubitemid 43854964)
78. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superiorprognostic value than triple-negativephenotype. Clin Cancer Res 2008; 14: 1368-76. (Pubitemid 351413917)
79. Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27: 1168-76.
80. Livasy CA,perou CM, Karaca G, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007; 38: 197-204. (Pubitemid 46096566)
81. Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009; 15: 2302-10.
82. Millar EK, GrahampH, O'Toole SA, et al.prediction of local recurrence, distant metastases, and death after breast-conserving therapy in earlystage invasive breast cancer using a five-biomarkerpanel. J Clin Oncol 2009; 27: 4701-8.
83. Millar EK, Anderson LR, McNeil CM, et al. BAG-1predictspatient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. Br J Cancer 2009; 100: 123-33.
84. Fisher B, Jeong J, Dignam J, et al. Findings from recent National Surgical Adjuvant Breast and Bowelproject adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001; 30: 62-6.
85. Ross JS, Hatzis C, Symmans WF,pusztai L, Hortobagyi GN. Commercialized multigenepredictors of clinical outcome for breast cancer. Oncologist 2008; 13: 477-93. (Pubitemid 351872866)
86. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay topredict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26. (Pubitemid 40051905)
87. Bryant J. Oncotype DX correlates more closely withprognosis than Adjuvant Online. 9th International Conference onprimary Therapy of Early Breast Cancer, St Gallen, Switzerland, Jan 26-29, 2005.
88. Habel LA, Shak S, Jacobs MK, et al. Apopulation-based study of tumor gene expression and risk of breast cancer death among lymph nodenegativepatients. Breast Cancer Res 2006; 8: R25.
89. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89: 1673-82. (Pubitemid 27508191)
90. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-34. (Pubitemid 46622311)
91. Albain KS, Barlow WE, Shak S, et al.prognostic andpredictive value of the 21-gene recurrence score assay inpostmenopausal women with nodepositive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11: 55-65.
92. Asad J, Jacobson AF, Estabrook A, et al. Does oncotype DX recurrence score affect the management ofpatients with early-stage breast cancer? Am J Surg 2008; 196: 527-9.
93. Lyman GH, Cosler LE, Kuderer NM, Hornberger J. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based onprognostic andpredictive validation studies. Cancer 2007; 109: 1011-8. (Pubitemid 46435378)
94. Cuzick J, Dowsett M, Wale C, et al.prognostic value of a combined ER,pgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score - results from TransATAC. San Antonio Breast Cancer Symposium, Dec 10-13, 2009, Abstract 74.
95. Francis GD, Dimech M, Giles L, Hopkins A. Frequency and reliability of oestrogen receptor,progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assuranceprogram. J Clinpathol 2007; 60: 1277-83. (Pubitemid 350084552)
96. Kelly CM, Krishnamurthy S, Bianchini G, et al. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 2010; 116: 5161-7.
97. Tang G, Cuzick J,Wale C, et al. Recurrence risk of node-negative and ERpositive early-stage breast cancerpatients by combining recurrence score,Pathologic, and clinical information: A meta-analysis approach. J Clin Oncol 2010; 28 (Suppl): abstr 509.
98. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expressionprofilingpredicts clinical outcome of breast cancer. Nature 2002; 415: 530-6. (Pubitemid 34130608)
99. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as apredictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009. (Pubitemid 35461656)
100. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-geneprognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-92. (Pubitemid 44390989)
101. Michiels S, Koscielny S, Hill C.prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005; 365: 488-92. (Pubitemid 40215731)
102. Koscielny S. Critical review of microarray-basedprognostic tests and trials in breast cancer. Curr Opin Obstet Gynecol 2008; 20: 47-50.
103. Fan C, Oh DS, Wessels L, et al. Concordance among geneexpression- basedpredictors for breast cancer. N Engl J Med 2006; 355: 560-9. (Pubitemid 44200649)